Replies to post #43036 on MultiCell Technologies Inc (MCET)

[TPX]

anticancer and antiviral therapeutics - MultiCell Technologies

Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485
Latest Information Update: 04 Nov 2017

At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
Mechanism of Action Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases

Preclinical Viral hepatitis
No development reported Cancer; Hepatocellular carcinoma

http://adisinsight.springer.com/drugs/800025804

[TPX]

https://www.pacermonitor.com/public/case/22944494/Multicell_Immunotherapeutics,_Inc_v_GT_Biopharma,_Inc,_and_its_predecessors_Oxis_International,_Inc_and_Oxis_Biotech,_Inc#